Apyx Medical Corp Dossier - Source-backed chat

Apyx Medical Corp

APYXNASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)1.26

Intrinsic Value $3.35median of 2 methodsbased on filings through 30 Jun 2026

Market Price $2.45Price as of 30 Sep 2026

UndervaluedIntrinsic value is 37% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $103.2M

Enterprise Value $110.9M

Shares Outstanding 44.2M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Apyx Medical Corp is transitioning from a single-technology company to a comprehensive body contouring platform leader through its newly launched AYON Body Contouring System. The company is uniquely positioned to capitalize on the massive surge in demand for skin tightening procedures driven by the widespread adoption of GLP-1 weight-loss therapies. With a leaner cost structure, improved gross margins, and narrowed operating losses, Apyx is on a clear path toward sustainable profitability and positive EBITDA by the end of 2026.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$6.00

Mean target$6.60

High · most bullish analyst$8.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$3.0015%

Slower-than-expected adoption of the AYON system due to macroeconomic pressures on elective cosmetic procedures or intense competition from established aesthetic device players. Operating cash burn persists, and the company fails to meet the revenue covenants under its $37.5M Perceptive Credit Agreement, forcing a dilutive equity raise or renegotiation of debt terms under unfavorable conditions.

Base CaseCentral scenario

$6.6060%

Matches the consensus mean

Apyx successfully executes its commercial strategy for AYON, meeting its upwardly revised FY2026 revenue guidance of $59.0M to $60.0M. Gross margins stabilize between 62% and 63%, and operating expenses are kept strictly below $45.0M. The company achieves positive Adjusted EBITDA by late 2026, and its existing cash reserves of $31.1M provide sufficient runway through 2027 without requiring dilutive financing.

Bull CaseUpside scenario

$8.0025%

Accelerated adoption of the AYON platform and rapid market penetration of the newly cleared power liposuction capability drive 2026 revenues above the high end of guidance ($60M+). Strong demand from post-GLP-1 patients seeking skin tightening treatments leads to exponential growth in high-margin single-use handpiece sales, expanding gross margins beyond 65% and achieving full-year net profitability ahead of schedule.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

The AYON Body Contouring System is a highly innovative, all-in-one platform that integrates fat removal, closed-loop contouring, electrosurgical capabilities, and Renuvion tissue contraction, streamlining surgeon workflows.
Strong tailwinds from GLP-1 weight-loss therapies, where skin laxity is a primary patient concern, driving a structural shift toward surgical skin-tightening solutions.
Significant margin expansion (gross margin up to 63.5% in Q1 2026) driven by a favorable product mix and high-margin consumable handpiece sales.
Disciplined cost management, with annual operating expenses reduced from over $53M to a projected cap of $45M in 2026, narrowing net losses.

Key Investment Risks

High sensitivity to macroeconomic downturns, as the majority of Renuvion and AYON procedures are elective and paid out-of-pocket by patients.
Strict financial covenants and high interest rate (12.0%) on its $37.5 million Perceptive term loan, which could pressure liquidity if revenue targets are missed.
Intense competition in the energy-based aesthetic device market from larger, better-capitalized competitors.

Thesis Invalidation Triggers

Failure to maintain total revenue above the minimum covenants required by the Perceptive Credit Agreement.
A material slowdown in AYON system placements or a decline in single-use handpiece utilization rates.
Unexpected regulatory setbacks or safety concerns arising from post-market surveillance of Renuvion or AYON systems.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.